A former Ernst & Young partner who was fined and disciplined by the Public Company Accounting Oversight Board over “reckless” accounting work for a pharmaceuticals company will challenge the case in a Washington federal appeals court.
The accounting oversight board concluded Mark E. Laccetti, an auditor for Ernst & Young, performed shoddy work for Taro Pharmaceuticals USA, a subsidiary of Israel-based Taro Pharmaceutical Industries Ltd. The U.S. Securities and Exchange Commission, which oversees the accounting board, last month upheld the reprimand.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
